QuatCy-I2 and MHI-I2 in Photodynamic Therapy
- PMID: 35300076
- PMCID: PMC8919274
- DOI: 10.1021/acsmedchemlett.1c00640
QuatCy-I2 and MHI-I2 in Photodynamic Therapy
Abstract
MHI-I2 (1) and QuatCy-I2 (2) were compared in terms of properties important for early-stage photodynamic therapy preclinical candidates. Thus, experiments were performed to monitor dark cytotoxicities, light/dark cytotoxicity ratios, selectivity of localization in tumors over other organs, and clearance from the plasma.
© 2022 American Chemical Society.
Conflict of interest statement
The authors declare no competing financial interest.
Figures
References
-
- Cheng P. H.; Pu K. Y. Molecular imaging and disease theranostics with renal-clearable optical agents. Nat. Rev. Mater. 2021, 6, 1095–1113. 10.1038/s41578-021-00328-6. - DOI
Grants and funding
LinkOut - more resources
Full Text Sources
